Clinically relevant drug interactions involving antimicrobials in a general hospital: a cross-sectional study

Objective: To assess the prevalence of pDDI involving antimicrobials and other standardized drugs in a large general hospital in the interior of São Paulo. Methods: quantitative study, with cross-sectional design and data collection by documentary analysis of hospital prescriptions from April to Ju...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Larissa PAVANELLO, Fátima G. FARHAT, Rafaela P. CARVALHO, Hellen T. GREGÓRIO
Formato: article
Lenguaje:EN
PT
Publicado: Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde 2021
Materias:
Acceso en línea:https://doaj.org/article/63d9deb03b604de8b4e5081ba9a6063d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Objective: To assess the prevalence of pDDI involving antimicrobials and other standardized drugs in a large general hospital in the interior of São Paulo. Methods: quantitative study, with cross-sectional design and data collection by documentary analysis of hospital prescriptions from April to June 2017. Results: 66 clinically relevant pDDI were found, which corresponded to approximately 7.3% of antimicrobial prescriptions, being 93.9% (62) contraindicated / severe and 6.1% (4) moderate. There was no difference in the prevalence of clinically relevant pDDIs between critical and non-critical inpatient, in addition to all contraindicated interactions (10) having occurred in the clinical and surgical units. The most prevalent pDDI were, with respective degrees of documentation, between vancomycin and amikacin (47% - reasonable), clarithromycin and simvastatin (13.6% - good), and ciprofloxacin and simvastatin (7.6% - good). Conclusion: For the proper prevention of potential drug-related problems, mechanisms to guarantee the quality of prescriptions by trained clinical pharmacists are of fundamental importance, in addition to alert systems and drug interaction information for the health team, then ensuring quality pharmacotherapy and patient safety.